Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study by Tolia, Vasundhara et al.
Wayne State University
Wayne State University Associated BioMed Central Scholarship
2010
Esomeprazole for the treatment of erosive
esophagitis in children: an international,
multicenter, randomized, parallel-group, double-
blind (for dose) study
Vasundhara Tolia
Wayne State University, vasu.tolia@gmail.com
Nader N. Youssef
Atlantic Health, Nader.Youssef@astrazeneca.com
Mark A. Gilger
Baylor College, magilger@texaschildrens.org
Barry Traxler
AstraZeneca LP, barry.traxler@astrazeneca.com
Marta Illueca
AstraZeneca LP, marta.illueca@astrazeneca.com
This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University
Associated BioMed Central Scholarship by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Tolia et al. BMC Pediatrics 2010, 10:41
doi:10.1186/1471-2431-10-41
Available at: http://digitalcommons.wayne.edu/biomedcentral/99
Tolia et al. BMC Pediatrics 2010, 10:41
http://www.biomedcentral.com/1471-2431/10/41
Open AccessR E S E A R C H  A R T I C L E
© 2010 Tolia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research articleEsomeprazole for the treatment of erosive 
esophagitis in children: an international, 
multicenter, randomized, parallel-group, 
double-blind (for dose) study
Vasundhara Tolia*1,5, Nader N Youssef2,6, Mark A Gilger3, Barry Traxler4 and Marta Illueca4
Abstract
Background: Acid suppression with a proton pump inhibitor is standard treatment for gastroesophageal reflux disease 
and erosive esophagitis in adults and increasingly is becoming first-line therapy for children aged 1-17 years. We 
evaluated endoscopic healing of erosive esophagitis with esomeprazole in young children with gastroesophageal 
reflux disease and described esophageal histology.
Methods: Children aged 1-11 years with endoscopically or histologically confirmed gastroesophageal reflux disease 
were randomized to esomeprazole 5 or 10 mg daily (< 20 kg) or 10 or 20 mg daily (≥ 20 kg) for 8 weeks. Patients with 
erosive esophagitis underwent an endoscopy after 8 weeks to assess healing of erosions.
Results: Of 109 patients, 49% had erosive esophagitis and 51% had histologic evidence of reflux esophagitis without 
erosive esophagitis. Of the 45 patients who had erosive esophagitis and underwent follow-up endoscopy, 89% 
experienced erosion resolution. Dilation of intercellular space was reported in 24% of patients with histologic 
examination.
Conclusions: Esomeprazole (0.2-1.0 mg/kg) effectively heals macroscopic and microscopic erosive esophagitis in this 
pediatric population with gastroesophageal reflux disease. Dilation of intercellular space may be an important 
histologic marker of erosive esophagitis in children.
Trial Registration: D9614C00097; ClinicalTrials.gov identifier NCT00228527.
Background
Gastroesophageal reflux disease (GERD) increasingly is
recognized in young children. A recent retrospective popu-
lation-based cohort study in Rochester, MN, found that the
incidence of GERD in children aged < 5 years was 0.9/
1,000 person-years [1]. Data on the prevalence and severity
of erosive esophagitis (EE) in young children are limited.
The prevalence of endoscopy- and biopsy-proven EE in one
study was 29% in 209 patients with GERD aged 18 months
to 10 years who had no neurologic abnormalities or congen-
ital esophageal anomalies [2]. A retrospective review of the
Pediatric Endoscopy Database System-Clinical Outcomes
Research Initiative (PEDS-CORI) demonstrated that, of
7,188 children aged ≤ 18 years who underwent endoscopy,
12.4% had EE [3].
Although endoscopy is a valuable tool in the diagnosis of
pediatric GERD and EE that provides macroscopic evi-
dence of erosions, histology is important because abnor-
malities may be present without visible lesions on
endoscopy. The North American Society for Pediatric Gas-
troenterology, Hepatology, and Nutrition (NASPGHAN)
guidelines for pediatric GERD recommend esophageal
biopsy in conjunction with diagnostic endoscopy [4]. If ero-
sions are identified, histology is not considered mandatory
for routine diagnosis of GERD. On histology, esophagitis is
diagnosed by the presence of epithelial hyperplasia, intra-
epithelial inflammation, vascular dilatation in papillae, bal-
loon cells, and ulceration [5]. Dilated intercellular spaces
have been described as an additional morphologic feature
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of GERD and esophagitis in infancy and childhood [6].
Mucosal biopsies also are recommended but not mandatory
in current pediatric endoscopy practice to exclude poten-
tially confounding diagnoses, such as eosinophilic or infec-
tious esophagitis and, less commonly, Barrett's esophagus
[4].
Acid suppression with a proton pump inhibitor (PPI) is
standard treatment for GERD and EE in adults [7] and
increasingly is becoming first-line therapy for children aged
1-17 years [4]. Currently three PPIs are approved by the US
Food and Drug Administration for the treatment of EE in
children: esomeprazole (1-17 years), omeprazole (2-16
years), and lansoprazole (1-17 years). Findings from direct
comparative studies in adults show that esomeprazole more
effectively heals EE in adults than omeprazole [8,9], lanso-
prazole [10,11], and pantoprazole [12]; however, similar
studies have not been conducted in pediatric populations. In
this report, we describe the healing of EE after esomepra-
zole treatment in children aged 1-11 years. Although not a
planned objective, this study allowed assessment of the use-
fulness of an adult classification system for EE in the pedi-
atric population, the Los Angeles (LA) Classification
System. In addition, because the literature lacks reports of
histologic data from young children with GERD, baseline
histology findings are reported here. The pharmacokinetic
profile of esomeprazole in children aged 1-11 years has
been published previously [13]. The primary safety and
clinical outcomes of esomeprazole treatment of GERD
from this study have been reported previously [14].
Methods
Study design and patients
The study design, methodology, eligibility criteria, patient
characteristics, and safety assessments have been described
in detail previously [14]. Children aged 1-11 years with
endoscopically confirmed GERD (determined by endos-
copy with or without biopsies) were screened and eligible
to be enrolled in an international, multicenter, randomized,
parallel-group, double-blind (for dose) study evaluating
once-daily esomeprazole during 8 weeks of treatment.
Patients with allergic or eosinophilic esophagitis, gastric
ulcers, bleeding lesions, strictures, and Barrett's esophagus
were excluded from the study. Erosive or histologic GERD
was documented; however, EE was not required. Endo-
scopic findings were classified using the LA Classification
System for EE (Table 1) [15]. As described in the literature
[14], macroscopic evidence for GERD seen on endoscopy
was documented and included hyperemia, ulcers, and nodu-
larity. Patients with no visible or definitive lesions under-
went a mucosal biopsy during baseline endoscopy for
histologic confirmation of reflux esophagitis. Valid pediat-
ric indicators of histologic reflux esophagitis were
recorded, including the presence of intraepithelial eosino-
phils or neutrophils and increased basal cell layer thickness
and papillary height [16,17]. Criteria for establishing and
documenting a clinical diagnosis of GERD were consistent
with the NASPGHAN guidelines [4].
Patients were assigned randomly to esomeprazole (Nex-
ium®; AstraZeneca LP, Wilmington, DE) 5 or 10 mg (chil-
dren ≥ 8 kg and < 20 kg) or 10 or 20 mg (children ≥ 20 kg)
once daily for 8 weeks. For children aged < 6 years or for
those who had difficulty swallowing the capsules, capsule
contents could be mixed with 1 tablespoon of applesauce.
Age-appropriate liquid antacid medication, MAALOX®
(aluminum hydroxide 225 mg/magnesium hydroxide 200
mg per 5 mL; Novartis Consumer, Parsippany, NJ) or
equivalent, was allowed as rescue medication. Parents or
guardians were instructed to administer rescue medication
according to product labeling or as prescribed by the physi-
cian. Rescue medication use was recorded; when applica-
ble, use in excess of the prescribed amount was reviewed
with the parent or guardian at each visit and documented.
Institutional Review Boards at each participating center
approved the study protocol (AstraZeneca study code
D9614C00097; ClinicalTrials.gov identifier
NCT00228527), and each patient's parent or guardian pro-
vided written informed consent with assent from the
patient, where applicable, before any study-specific proce-
dure was performed. Study procedures were conducted in
accordance with the ethical principles of the Declaration of
Helsinki and its amendments and with the International
Conference on Harmonization and Good Clinical Practice
guidelines.
Assessments
All procedures including upper endoscopic evaluation were
indicated clinically and represented standard practice at the
local institution. Accordingly, no patient underwent endos-
Table 1: Los Angeles Classification System for erosive 
esophagitis 
LA grade Description
A ≥1 Mucosal break ≤5 mm that does not 
extend between the tops of two mucosal 
folds
B ≥1 Mucosal break ≥5 mm long that does not 
extend between the tops of two mucosal 
folds
C ≥1 Mucosal break that is continuous between 
the tops of two or more mucosal folds but 
that involves < 75% of the esophageal 
circumference
D ≥1 Mucosal break, which involves ≥75% of 
the esophageal circumference
LA: Los Angeles.
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copy solely for study enrollment or other research purposes.
An upper gastrointestinal endoscopy was performed during
screening at the discretion of the investigator. Patients who
had a previous endoscopic diagnosis of EE within 2 weeks
of screening and were candidates for PPI therapy were not
required to have an additional endoscopy if a full endo-
scopic report with photographic documentation was avail-
able. Histologic evidence was required for patients who
were newly diagnosed with GERD if the patient did not
have EE to confirm the presence of esophagitis. Endoscopy
with biopsy was used to document the extent of EE, deter-
mine the presence of Helicobacter pylori, and rule out cer-
tain exclusionary conditions. For patients who had EE at
baseline, a repeat endoscopy was planned after 8 weeks of
esomeprazole treatment to document healing. GERD-
related symptoms were reported by the parents or guardians
on behalf of the patients. These symptoms were derived
from the NASPGHAN guidelines [4] and included heart-
burn (burning feeling rising from the stomach or lower part
of the chest toward the neck), acid regurgitation (perception
of unpleasant-tasting fluid backing up into the throat and/or
mouth), epigastric pain (perception of discomfort located in
the central upper portion of the abdomen), vomiting (gastric
contents are forced up to and out of the mouth), difficulty
swallowing (difficulty passing anything through the phar-
ynx or esophagus), and feeding difficulties (food refusal,
choking with food/drink, and/or poor weight gain).
The LA Classification System was used to grade EE
(Table 1) [15]. Other pediatric endoscopic GERD descrip-
tors of esophagitis as reported in the literature were
accepted, and appropriate histologic confirmation was
obtained when indicated [18,19]. Per routine standards of
pediatric medical practice [20], mucosal biopsy specimens
were obtained during baseline endoscopy for histologic
confirmation of GERD-related esophagitis in patients with-
out visible or definitive lesions [21]. If needed, biopsy spec-
imens were recommended to be taken from the distal
esophagus, approximately 0.5 cm above the Z-line
(squamocolumnar junction) based on the investigator's
assessment of landmarks, and from any area with an abnor-
mal appearance. Biopsy was optional for patients with
endoscopically visible lesions, and specimens were
obtained for medical reasons only at the discretion of the
investigator. Biopsy specimens were evaluated at each
study site for histologic findings, including the number of
intraepithelial eosinophils and neutrophils [4,22,23], lym-
phocytes per high power field, elongated length of papillae
(> 50% to 75% of epithelial thickness) [4,21,22], increased
thickness of the basal cell layer (> 20% to 25% of total epi-
thelial thickness) [4,21,22], and increased total epithelial
thickness. Histologic changes were recorded [24-26] but
not required as a research procedure. Histologic changes
were characterized based on the standards from each
pathologist's individual institution; findings were recorded
on the case report form (e.g., those listed previously in
Methods).
Safety was assessed by adverse events (AEs) spontane-
ously reported by the parent or guardian, reported in
response to an open question from the investigator, or
revealed by observation or change from baseline conditions
or values in medical histories, physical examinations, vital
signs, and clinical laboratory evaluations.
Statistical analysis
Outcome analyses of EE healing were conducted on the
intention-to-treat (ITT) population dataset. The ITT popula-
tion was defined as all patients who had baseline and one or
more postbaseline measurements, one or more ingested
doses of study medication, and completion of a posttreat-
ment endoscopy. EE was considered healed if no signs of
erosion were observed on final endoscopy. The percentage
of patients with healed esophageal erosions and the 95%
confidence interval for the total were calculated by Astra-
Zeneca (B.T.). The International Conference on Harmoni-
zation guideline E1 recommends randomization of ≥ 100
patients for the safety database of any drug. Therefore, the
study was designed to randomize ≥ 100 patients to ensure
that ≥ 40 patients in each age group would complete the
study.
Results
Patient characteristics
The study was conducted between October 2004 and
November 2005 at 24 sites within Belgium (three sites),
France (two sites), Italy (four sites), and the United States
(15 sites). A total of 109 patients were randomized in the
study and included in the ITT population. Of the 49 patients
who failed the screening process, four had eosinophilic
esophagitis, 27 had no endoscopic proof of reflux esophagi-
tis, two had a normal endoscopy, and 16 were not related to
endoscopy (Figure 1). Baseline demographic and nonphysi-
cal disease characteristics were similar across all treatment
groups (Table 2). Fifty-two patients (47.7%) were aged 1-5
years, and 57 (52.3%) were aged 6-11 years. The mean age
was 5.7 years. Height, weight, and body mass index also
were similar across dose groups within each weight stratum
(< 20 kg or ≥ 20 kg). Esomeprazole doses ranged 0.2-1.0
mg/kg. The most common presenting GERD symptoms at
baseline were heartburn (52%), acid regurgitation (55%),
and epigastric pain (55%) (Table 2). The distribution of
patients met the study goal of ≥ 40 evaluable patients in
each age group.
Of 109 patients randomized, 53 (49%) had EE at baseline
and 56 (51%) had reflux esophagitis without EE (Table 3).
Of 83 patients enrolled from study sites within the United
States, 36 (43%) had EE; of 26 patients enrolled from Euro-
pean sites, 17 (65%) had EE. The proportion of patients
with EE and other reflux esophagitis was distributed evenly
Tolia et al. BMC Pediatrics 2010, 10:41
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across treatment groups. All but two patients had LA grades
A or B EE (Table 3); one patient had grade C (< 20 kg/10-
mg group), and the other had grade D (≥ 20 kg/20-mg
group) [14]. Hiatal hernia was documented in seven chil-
dren in the < 20-kg group and 12 children in the ≥ 20-kg
group. Other esophageal abnormalities (e.g., hyperemia,
esophageal ulcers, nodularity, prolapse gastropathy) were
present in 55 children (n = 21, < 20 kg; n = 34, ≥ 20 kg)
(Table 3). Of 109 patients in the ITT population, 107 had a
biopsy. Investigators reported other gastric and duodenal
abnormalities when detected. Other histologic findings
were present in the esophagus at baseline (Table 4). Dila-
tion of intercellular space was reported in 24% of patients.
Esophageal healing
Of 53 patients with EE at baseline, eight did not undergo
final endoscopies or were otherwise excluded from the ITT
population because of premature study discontinuation (n =
4), revised diagnosis (n = 2), endoscopy performed outside
the study timeframe (n = 1), or failure to give reason for not
performing endoscopy (n = 1). Of 45 patients who had EE
at baseline and underwent posttreatment endoscopy, EE
was healed in 40 patients (89%) (Figure 2). Healing rates
were similar across all esomeprazole dose groups. Healing
of EE did not occur in five patients (11%): two patients in
the 20-mg group were rated as improved but not completely
healed (i.e., ≥ 1 LA grade improvement), and three patients
in the 10-mg groups exhibited no change from baseline (n =
2, < 20 kg; n = 1, ≥ 20 kg). Patients whose EE was not
healed received doses in the range of 0.17-0.66 mg/kg.
Adverse events
Safety data were evaluable in 108 of 109 patients random-
ized and are described in detail elsewhere [14]. In brief, 13
AEs considered by the investigator to be related to esome-
prazole treatment occurred in 10 of 108 patients (9.3%).
The most commonly reported treatment-related AEs were
diarrhea (2.8%; n = 3, 10-mg/< 20 kg group), headache
(1.9%; n = 2, 10-mg/≥ 20 kg group), and somnolence
(1.9%; n = 1, 5-mg/< 20 kg group and n = 1, 10-mg/< 20 kg
group).
Discussion
Based on this study, the use of esomeprazole across a wide
dose range (0.2-1.0 mg/kg) daily for ≤ 8 weeks resulted in
significant healing of macroscopic and histologic esophagi-
tis in children aged 1-11 years. Few studies of PPI treatment
of young children with GERD, including those with EE, are
available [27-34]. The results of the present study provide
additional evidence to support the safe use and tolerability
of PPIs in children with GERD with or without EE [4].
Moreover, to our knowledge, this study is the first to pro-
spectively report the use of the LA Classification System
[15] to diagnose and document EE healing in young chil-
dren. Several EE classification systems exist in the adult lit-
erature (e.g., Hetzel-Dent or Savary-Miller classifications),
which have been adapted previously for pediatric studies
[31,32]. Our results demonstrate that the LA Classification
System can be used successfully to classify the severity of
EE in children. The majority of children with EE in this
study had LA grades A and B (29% and 17%, respectively).
The LA classification system offered a simple, straightfor-
ward method to grade EE and document healing in the
absence of erosions. The use of the LA classification sys-
tem in children may allow for comparison between pediat-
ric and adult data to unify our knowledge of healing of EE;
however, it has not been validated yet for use in pediatric
populations.
The doses used in this study were determined from the
results of a pharmacokinetic study of esomeprazole in chil-
dren aged 1-11 years, an extrapolation of the recommended
adult esomeprazole doses using an exposure-response rela-
tionship reported previously [13], and the assumption that
most children < 12 years weigh 8-60 kg. For ethical reasons
in a population of children with confirmed GERD, this
study did not include a placebo control group but was dou-
ble blind to dosage. The lack of a control group is a poten-
tial limitation to this study. Furthermore, the assessment of
the clinical outcome of EE was not controlled and was not
the primary end point of the study; however, more impor-
tantly, the clinical benefit of esomeprazole in healing EE
was documented. In addition, the small number of patients
in each treatment group precluded a comparison between
doses.
In the present study, the prevalence of EE (49%) in chil-
dren aged 1-11 years was higher than that reported previ-
ously in children (12.4%) [3]. Baseline endoscopic and
histologic data showed that 18% of patients had esophageal
nodules, which have been shown to be a possible predictor
of EE in the PEDS-CORI [18]. Our results suggest that
dilation of intercellular space may be a potential histologic
diagnostic criterion for EE [6]. Dilation of intercellular
Figure 1 Patient disposition. EE: erosive esophagitis.
158 Patients screened for eligibility
• Did not have endoscopic proof 
of reflux esophagitis, n = 27
• Presence of eosinophilic 
esophagitis, n = 4
• Had normal endoscopy, n = 2
• Failed for reasons unrelated 
to endoscopy, n = 16
109 Randomized
53 Patients had EE 56 Patients did not have EE
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Table 2: Demographic and baseline disease characteristics of all patients enrolled (N = 109)
Children < 20 kg Children ≥ 20 kg
Characteristic Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole
10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole
10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole
20 mg
(0.3-1.0 mg/kg)
(n = 29)
Girls, n (%) 14 (53.8) 14 (60.9) 14 (45.2) 11 (37.9)
Mean age, years 2.1 2.5 8.5 8.3
Age in years, n (%)
1 12 (46.2) 8 (34.8)
2 6 (23.1) 5 (21.7)
3 4 (15.4) 4 (17.4)
4 2 (7.7) 3 (13.0) 1 (3.2) 2 (6.9)
5 1 (3.8) 2 (8.7) 1 (3.2) 1 (3.4)
6 1 (3.8) 1 (4.3) 2 (6.5) 0
7 5 (16.1) 3 (10.3)
8 5 (16.1) 9 (31.0)
9 8 (25.8) 6 (20.7)
10 3 (9.7) 6 (20.7)
11 6 (19.4) 2 (6.9)
Race, n (%)
White 19 (73.1) 19 (82.6) 26 (83.9) 25 (86.2)
Black 7 (26.9) 4 (17.4) 5 (16.1) 3 (10.3)
Other 0 0 0 1 (3.4)
Mean height (range), cm 90.0 (70-109) 94.2 (80-119) 134.5 (108-168) 134.5 (112-159)
Mean weight (range), kg 12.8 (8-18) 14.1 (10-18) 35.5 (20-58) 34.5 (21-60)
Mean body mass index (SD), 
kg/m2
15.7 (2.1) 15.9 (1.7) 19.3 (4.8) 18.6 (3.9)
Helicobacter pylori-positive, 
n (%)
0 1 (4.3) 0 0
Symptoms at baseline, n (%)
Heartburn 15 (57.7) 10 (43.5) 19 (61.3) 13 (44.8)
Acid regurgitation 18 (69.2) 11 (47.8) 20 (64.5) 11 (37.9)
Epigastric pain 17 (65.4) 13 (56.5) 15 (48.4) 15 (51.7)
Vomiting 13 (50.0) 7 (30.4) 3 (9.7) 5 (17.2)
Eating difficulties 15 (57.7) 13 (56.5) 9 (29.0) 7 (24.1)
Difficulty swallowing 6 (23.1) 8 (34.8) 5 (16.1) 6 (20.1)
Extraesophageal symptoms 
at baseline, n (%)
n = 12 n = 12 n = 16 n = 13
Hoarseness 4 (33.3) 4 (50.0) 4 (25.0) 7 (53.8)
Coughing 8 (66.7) 9 (75.0) 7 (43.8) 7 (53.8)
Gagging 5 (41.7) 6 (50.0) 2 (12.5) 4 (30.8)
Wheezing/stridor 1 (8.3) 1 (8.3) 2 (12.5) 0 (0)
Mean (range) esomeprazole 
dose, mg/kg
0.4 (0.3-0.6) 0.7 (0.6-1.0) 0.3 (0.2-0.5) 0.6 (0.3-1.0)
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Table 3: Endoscopic findings at baseline, n (%)
Children < 20 kg Children ≥20 kg
Category Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole 10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole 10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole 20 mg
(0.3-1.0 mg/kg)
(n = 29)
Total
(N = 109)
Other reflux esophagitis 14 (54) 11 (48) 15 (48) 16 (55) 56 (52)
Erosive esophagitis 12 (46) 12 (52) 16 (52) 13 (45) 53 (49)
LA grade A 6 (23) 6 (26) 11 (36) 9 (31) 32 (29)
LA grade B 6 (23) 5 (22) 5 (16) 3 (10) 19 (17)
LA grade C 0 1 (4) 0 0 1 (1)
LA grade D 0 0 0 1 (3) 1 (1)
Hiatal hernia 4 (15) 3 (13) 8 (26) 4 (14) 19 (17)
Other abnormality* 11 (42) 10 (44) 16 (52) 18 (62) 55 (50)
*Abnormalities occurring in ≥4 patients were nodularity (n = 20 [18%]), erythema/hyperemia (n = 23 [21%]), edema (n = 11 [10%]), prominent 
esophageal folds (n = 11 [10%]), and friability (n = 4 [4%]).
LA: Los Angeles.
Table 4: Baseline histologic data of the esophagus, n (%)*
Children < 20 kg Children ≥20 kg
Category Esomeprazole
5 mg
(0.3-0.6 mg/kg)
(n = 26)
Esomeprazole 10 mg
(0.6-1.0 mg/kg)
(n = 23)
Esomeprazole 10 mg
(0.2-0.5 mg/kg)
(n = 31)
Esomeprazole 20 mg
(0.3-1.0 mg/kg)
(n = 29)
Total
(N = 109)
Eosinophilic densification 4 (15) 3 (13) 8 (26) 12 (41) 27 (25)
Intraepithelial eosinophils† 5 (19) 9 (39) 13 (42) 13 (45) 40 (37)
Intraepithelial neutrophils† 5 (19) 1 (4) 6 (19) 3 (10) 15 (14)
Intraepithelial lymphocytes† 13 (50) 9 (39) 17 (55) 14 (48) 53 (49)
Elongated length of papillae 16 (62) 10 (44) 16 (52) 19 (66) 61 (56)
Increased thickness of basal cell layer 15 (58) 13 (56) 15 (48) 19 (66) 62 (57)
Increased total epithelial thickness 11 (42) 10 (44) 10 (32) 10 (34) 41 (38)
Dilation of intercellular spaces
Absent/NR 21 (81) 21 (91) 24 (77) 17 (59) 83 (76)
< 25% 3 (12) 2 (9) 5 (16) 10 (34) 20 (18)
≥25% 2 (8) 0 2 (6) 2 (7) 6 (6)
Columnar epithelium
Present 4 (15) 4 (17) 3 (10) 4 (14) 15 (14)
Not
assessable
1 (4) 5 (22) 7 (23) 4 (14) 17 (16)
Cardia mucosa 2 (8) 3 (13) 1 (3) 4 (14) 10 (9)
Corpus mucosa 1 (4) 1 (4) 3 (10) 1 (3) 6 (6)
Diagnosis of microscopic reflux 
esophagitis
20 (77) 18 (78) 24 (77) 24 (83) 86 (79)
*107 Patients had a biopsy.
†Per high power field.
NR: not reported.
Tolia et al. BMC Pediatrics 2010, 10:41
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space was reported in 24% of the patients in this study
(reporting this information was not mandatory), whereas
49% of patients had endoscopically confirmed EE.
Although these potential histologic predictors of EE were
identified in patients in this study, we cannot determine
accurately the incidence of these potential markers because
not every patient was evaluated for these histologic changes
in a standardized manner. Determination of the true inci-
dence of these markers in children is an area of future
research. Large epidemiologic studies in children also are
needed to determine the role of extraesophageal symptoms
and concomitant conditions (e.g., asthma) in GERD.
The criteria for establishing and documenting endoscopi-
cally proven GERD for study entry were consistent with
those previously recommended by NASPGHAN [4,20].
Endoscopic findings were required to be documented at
study entry to allow for full characterization of the extent of
GERD, including the presence and severity of EE and other
gross findings. Furthermore, histologic assessment, when
available, aided in excluding the diagnosis of other esopha-
geal disorders, such as eosinophilic esophagitis. Although
biopsy specimens were not evaluated by a central reader
and therefore were not standardized, the histopathologic
data obtained contribute to the existing sparse literature in
this patient population. Additionally, the reason for a
greater proportion of patients with EE in the European
study sites compared with the United States study sites is
not clear. The reasons for such geographic variation need to
be studied further.
In this pediatric population, the clinical course and mani-
festations of the spectrum of GERD symptoms appear to be
similar to those seen in adults. The current study continues
to expand on the knowledge and potential management
options that are available for young children with GERD
and EE, and adult efficacy data may be extrapolated to this
age group [3,4,35-37]. An 8-week treatment duration repre-
sents the approximate time needed for healing of EE in
adults [8-12]. Guidelines for treatment of pediatric GERD
recommend a 3-month course of acid suppression treatment
for children who have GERD symptoms [4]. The results of
the present study parallel the results from those of previous
studies of PPIs in adults with EE and provide additional
support for the use of esomeprazole treatment for EE in
young children.
Conclusion
The findings of this study showed that an 8-week course of
esomeprazole treatment (0.2-1.0 mg/kg) healed esophageal
erosions in 89% of children aged 1-11 years who had EE.
Although the LA Classification System was used success-
fully to grade EE in this study, the development of a new
pediatric-specific scoring system is suggested. For exam-
ple, a complementary scoring system is needed to accom-
modate other pediatric endoscopic findings described in the
literature, such as esophageal nodules [18]. Histologic
assessment showed frequent mucosal damage in this popu-
lation and provides further support for the use of histology
to augment endoscopic findings in pediatric patients with
GERD.
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